Aytu BioPharma Inc (STU:AY20)
€ 2.88 -0.02 (-0.7%) Market Cap: 16.52 Mil Enterprise Value: 13.72 Mil PE Ratio: 0 PB Ratio: 0.58 GF Score: 33/100

Q4 2022 Aytu Biopharma Inc Earnings Call Transcript

Sep 27, 2022 / 08:30PM GMT
Release Date Price: €139
Operator

Good afternoon, everyone, and welcome to Aytu BioPharma's Fourth Quarter and Fiscal Year 2022 Financial Results Conference Call. (Operator Instructions) It's now my pleasure to turn the floor over to your host, Robert Blum with Lytham Partners. Sir, the floor is yours.

Robert A. Blum
Lytham Partners, LLC - Managing Partner

All right. Thank you very much. Good afternoon, everyone. And as the operator said, thank you for joining us for today's Aytu BioPharma Fourth Quarter and Fiscal Year 2022 Financial Results Conference Call. Joining us on today's call is Aytu's CEO, Josh Disbrow; and the company's Chief Financial Officer, Mark Oki. At the conclusion of today's prepared remarks, we will open the call for a question-and-answer session.

I'd like to remind everyone that today's call is being recorded. A replay of today's call will be available by using the telephone numbers and conference ID provided in the earnings press release issued earlier today.

Finally, I'd also like to call to your attention the customary safe harbor disclosure

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot